Compare Pfizer Inc (PFE) vs Banco Santander SA (SAN) Price & Performance

Pfizer (PFE) trades at $24.75, down 1.2% on the day, with a neutral technical outlook. The company maintains strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $0.75 beating expectations of $0.722. Pfizer demonstrates robust profitability with a 73.51% gross margin and 11.83% net income margin, though revenue has moderated from pandemic peaks. Recent news highlights the company's focus on AI drug discovery and pipeline development.

Pfizer presents a value opportunity trading below analyst consensus target of $28.25, with 38% of analysts rating it Buy. The stock offers a solid dividend yield with recent $0.43 payments. Key risks include patent expirations and revenue normalization post-COVID, while catalysts include obesity and oncology pipeline developments in 2026.

Santander (SAN) trades at $13.65, up 0.74% with mixed technical signals showing bearish moving averages but oversold RSI. The company reported Q1 2026 EPS beat ($0.41 vs $0.29 expected) and maintains strong profitability with 26.72% net margin and 16.18% ROE. Recent developments include the $12.2 billion Webster Bank acquisition and AI-driven cost initiatives targeting $1.15 billion in business value.

SAN offers value with a 13.23 P/E and dividend yield near 4.4%, supported by 64% analyst buy ratings. Key risks include declining cash flows (-$28.13B in 2024) and Spanish antitrust probes. The stock's upside depends on successful integration of acquisitions and AI efficiency gains offsetting macroeconomic pressures on European banking.